FDA panel to wrangle with Actavis/AstraZeneca antibiotic combo
This article was originally published in Scrip
Executive Summary
The FDA's Anti-Infective Drugs Advisory Committee (AIDAC) on 5 December must wrangle with whether adding a novel beta-lactamase inhibitor, avibactam, to ceftazidime, a well-established beta-lactam, would effectively work against resistant pathogens for which the latter drug would otherwise have no activity alone.